Insider Selling: DexCom, Inc. (NASDAQ:DXCM) EVP Sells 777 Shares of Stock

DexCom, Inc. (NASDAQ:DXCMGet Rating) EVP Chad Patterson sold 777 shares of the business’s stock in a transaction on Monday, May 9th. The stock was sold at an average price of $342.77, for a total value of $266,332.29. Following the completion of the transaction, the executive vice president now directly owns 13,675 shares of the company’s stock, valued at $4,687,379.75. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Chad Patterson also recently made the following trade(s):

  • On Monday, April 11th, Chad Patterson sold 776 shares of DexCom stock. The stock was sold at an average price of $498.75, for a total value of $387,030.00.

Shares of DXCM stock opened at $327.43 on Wednesday. The stock’s 50-day simple moving average is $450.92 and its 200-day simple moving average is $491.61. The company has a debt-to-equity ratio of 0.90, a quick ratio of 4.79 and a current ratio of 5.27. The firm has a market capitalization of $32.13 billion, a PE ratio of 158.18, a P/E/G ratio of 6.15 and a beta of 1.05. DexCom, Inc. has a fifty-two week low of $318.45 and a fifty-two week high of $659.45.

DexCom’s stock is going to split on the morning of Friday, June 10th. The 4-1 split was announced on Friday, March 25th. The newly created shares will be issued to shareholders after the market closes on Thursday, June 9th.

DexCom (NASDAQ:DXCMGet Rating) last announced its quarterly earnings data on Thursday, April 28th. The medical device company reported $0.32 earnings per share for the quarter, missing analysts’ consensus estimates of $0.52 by ($0.20). DexCom had a net margin of 8.23% and a return on equity of 12.42%. The firm had revenue of $628.80 million during the quarter, compared to analyst estimates of $623.97 million. During the same period in the prior year, the company posted $0.33 earnings per share. The firm’s revenue for the quarter was up 24.5% on a year-over-year basis. Sell-side analysts forecast that DexCom, Inc. will post 3.29 earnings per share for the current year.

Several research analysts have recently commented on DXCM shares. Zacks Investment Research lowered DexCom from a “hold” rating to a “sell” rating and set a $452.00 price target for the company. in a research report on Tuesday, February 1st. Bank of America started coverage on DexCom in a research report on Wednesday, March 2nd. They set a “buy” rating on the stock. Citigroup reduced their target price on DexCom from $660.00 to $630.00 in a research report on Friday, February 11th. StockNews.com started coverage on DexCom in a research report on Thursday, March 31st. They set a “hold” rating on the stock. Finally, SVB Leerink reduced their target price on DexCom from $565.00 to $500.00 in a research report on Friday, April 29th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and fifteen have given a buy rating to the company’s stock. According to MarketBeat, DexCom currently has an average rating of “Buy” and an average target price of $547.82.

Institutional investors and hedge funds have recently modified their holdings of the company. Riverview Trust Co purchased a new stake in shares of DexCom in the first quarter worth about $25,000. Rise Advisors LLC purchased a new stake in shares of DexCom in the fourth quarter worth about $26,000. Equitec Proprietary Markets LLC purchased a new stake in shares of DexCom in the fourth quarter worth about $29,000. Benjamin F. Edwards & Company Inc. purchased a new stake in shares of DexCom in the fourth quarter worth about $37,000. Finally, American National Bank purchased a new position in DexCom during the fourth quarter worth approximately $37,000. Hedge funds and other institutional investors own 93.26% of the company’s stock.

DexCom Company Profile (Get Rating)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system.

Read More

Insider Buying and Selling by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.